[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627100":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":32,"centralContacts":36,"locations":46,"responsibleParty":68,"collaborators":23,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":23,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":49,"whyStopped":23,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University of Regensburg","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Verum accelerated home-based tDCS","EXPERIMENTAL","10 patients will receive active tDCS during a three-week intervention (accelerated: twice daily).",[13],"Device: Transcranial direct current stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham accelerated home-based tDCS","PLACEBO_COMPARATOR","10 patients will receive sham tDCS during a three-week intervention (accelerated: twice daily) with the opportunity to get active tDCS after study completion.",[13],{"label":20,"type":21,"description":22,"interventionNames":23},"Waiting list","NO_INTERVENTION","10 patients will have to wait for three weeks before the beginning ot the active tDCS intervention.",null,[25],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DEVICE","Transcranial direct current stimulation","Non-invasive brain stimulation techniques, such as transcranial direct current stimulation (tDCS), have gained increasing attention in recent years in both research and the treatment of various psychiatric disorders (Alonzo et al., 2019; Lefaucher et al., 2017).\n\nCompared to other neuromodulation methods, such as transcranial magnetic stimulation (TMS), tDCS offers the advantage of mobile or outpatient use, including home-based application. tDCS devices are small, portable, and cost-effective, and they are associated with a favorable side-effect profile (Alonzo et al., 2019).",[15,9],[31],"tDCS",[33],{"name":34,"affiliation":5,"role":35},"Berthold Langguth, Prof, PhD","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":23,"email":41},"Stefan Schoisswohl, PD, PhD","CONTACT","+499419411284","stefan.schoisswohl@ukr.de",{"name":43,"role":39,"phone":44,"phoneExt":23,"email":45},"Ulrike Stadler","+499419411256","tms-psy-r@medbo.de",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Psychiatry and Psychotherapy, Center of Neuromodulation \u002F TMS, University Regensburg","RECRUITING","Regensburg","Bavaria","93053","Germany","DE",{"type":56,"coordinates":57},"Point",[58,59],12.10161,49.01513,{"lat":59,"lon":58},[62,66],{"name":63,"role":39,"phone":64,"phoneExt":23,"email":65},"Stefan Schoisswohl, PhD","+49941 941 1284","stefan.schoisswohl@medbo.de",{"name":43,"role":39,"phone":67,"phoneExt":23,"email":45},"+49 941 941 2056",{"type":35,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Berthold Langguth, MD, Ph.D.","Clinical Professor, MD, Ph.D.","100627100","accelerated-treatment-of-depressive-patients-with-tdcs-100627100",false,"NCT07444242","Accelerated Treatment of Depressive Patients With tDCS","Accelerated Treatment of Depressive Patients With tDCS (Twice Per Day) - a Placebo Controlled Home-based Treatment","AcctDCS","Inclusion Criteria:\n\n* Sex: female, male, non-binary\n* Age: 18-70 years\n* Diagnosis of depression: no current or past psychiatric medication (current episode and history)\n* Provision of informed consent to participate\n* Sufficient proficiency in the German language\n\nExclusion Criteria:\n\n* Presence of contraindications for tDCS (e.g., electrical implants or metallic objects in the body such as a cardiac pacemaker or insulin pump, dermatological conditions affecting the scalp)\n* Neurological disorders (e.g., cerebrovascular events, neurodegenerative diseases, epilepsy, brain malformations, or a history of severe head injury)\n* Participation in another clinical trial on depression within the 3 months prior to treatment initiation\n* Pregnancy or breastfeeding","ALL","18 Years","70 Years",{"count":83,"type":84},30,"ESTIMATED","INTERVENTIONAL",[87],"NA","A randomized, controlled three-arm study is planned to investigate the effectiveness and feasibility of an accelerated home-based tDCS application (3 weeks of transcranial direct current stimulation at home, twice daily). A total of 30 patients with depression (10 per group), who are currently not taking and have no history of taking antidepressant medication, will be randomly assigned to either an active tDCS condition, a sham (placebo) tDCS condition, or a waitlist control group. The latter two groups will receive active tDCS treatment after completion of the control phase.\n\nThis study represents a continuation of the pilot study GSUND DAHOAM (Ethics approval: 20-2091-101; Dragon et al., 2024).",[90],"Major Depressive Disorder",[92,31,93],"Depression","Accelerated","2026-06-11",{"date":96,"type":97},"2026-06-15","ACTUAL",{"date":99,"type":97},"2026-04-01",{"date":101,"type":84},"2027-12-31",{"name":5,"class":6},1]